Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
04:52pm, Thursday, 02'nd Apr 2026
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 02'nd Apr 2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
04:05pm, Wednesday, 01'st Apr 2026
CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
04:05pm, Thursday, 19'th Mar 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
10:01am, Tuesday, 17'th Mar 2026
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
05:58pm, Monday, 09'th Mar 2026
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
08:00am, Tuesday, 03'rd Mar 2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Mar 2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease
Akebia Therapeutics Q4 Earnings Call Highlights
02:36am, Sunday, 01'st Mar 2026
Akebia Therapeutics (NASDAQ: AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
11:27am, Thursday, 26'th Feb 2026
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
07:00am, Thursday, 26'th Feb 2026
Q4 2025 net product revenues of $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
08:00am, Thursday, 19'th Feb 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended Decembe
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
04:57pm, Friday, 13'th Feb 2026
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
08:00am, Wednesday, 04'th Feb 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Feb 2026
CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
